MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-26-2026
Viatris Depreciation & Amortization 2011-2026 | VTRS
Annual Depreciation & Amortization Viatris
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.74 B | 3.03 B | 4.51 B | 2.22 B | 2.02 B | 2.11 B | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.51 B | 2.02 B | 2.77 B |
Quarterly Depreciation & Amortization Viatris
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 593 M | 583 M | 665 M | 575 M | 597 M | 691 M | 584 M | 591 M | 730 M | - | 2.16 B | 634 M | 736 M | - | 3.76 B | 2.74 B | 1.42 B | - | 1.26 B | 831 M | 415 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.76 B | 415 M | 1.09 B |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Harrow Health
HROW
|
1.32 M | $ 35.84 | 1.82 % | $ 1.32 B | USA |
 |
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
31 K | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
125 M | $ 8.27 | 3.25 % | $ 423 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Cumberland Pharmaceuticals
CPIX
|
4.9 M | $ 3.33 | 6.39 % | $ 46.8 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.04 M | - | - | $ 193 M |  Canada |
 |
Bausch Health Companies
BHC
|
1.26 B | $ 5.14 | 3.01 % | $ 1.88 B | Canada |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
Pacira BioSciences
PCRX
|
78.8 M | $ 23.39 | 0.8 % | $ 1.08 B | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
7.51 M | $ 4.42 | -0.23 % | $ 285 M | USA |
 |
Perrigo Company plc
PRGO
|
338 M | $ 9.65 | 0.1 % | $ 1.34 B | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
1.44 M | $ 1.08 | 4.37 % | $ 25.2 M | USA |
 |
Solid Biosciences
SLDB
|
1.64 M | $ 7.21 | 7.86 % | $ 631 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 2.39 | 2.13 % | $ 2.97 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 6.55 | 7.3 % | $ 259 M | USA |
 |
Tilray
TLRY
|
35.7 M | $ 6.98 | 4.8 % | $ 4.31 B | Canada |
 |
SCYNEXIS
SCYX
|
580 K | $ 0.91 | 1.27 % | $ 45.4 M | USA |
 |
Veru
VERU
|
268 K | $ 2.34 | 2.18 % | $ 316 M | USA |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
2.62 M | $ 0.62 | 5.0 % | $ 10.8 M |  China |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
13.6 M | $ 2.47 | 2.28 % | $ 325 M | USA |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 0.98 | 2.73 % | $ 105 M | Canada |
 |
cbdMD
YCBD
|
452 K | $ 0.8 | 4.04 % | $ 3.45 M | USA |
 |
Assertio Holdings
ASRT
|
30 M | $ 17.24 | 4.42 % | $ 110 M | USA |
 |
TherapeuticsMD
TXMD
|
922 K | $ 2.28 | -0.28 % | $ 23.8 M | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
219 K | - | - | $ 55.5 M | USA |